Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Receptor tyrosine kinases (RTKs) are cell-surface proteins that transmit growth and survival signals when activated by binding partners called ligands. Three RTK families are relevant here: VEGFR (vascular endothelial growth factor receptor), which drives formation of new blood vessels (angiogenesis); PDGFR (platelet-derived growth factor receptor), which supports the growth of supporting cells such as pericytes and fibroblasts that stabilize vessels and tumor stroma; and KIT, which regulates proliferation in certain blood-forming and other progenitor cells. Many solid tumors depend on angiogenesis to obtain oxygen and nutrients as they grow, and some also produce PDGF or KIT-driven signals that support tumor vasculature or the tumor cells themselves. A multi-kinase inhibitor blocks the catalytic activity of all three receptor types simultaneously by occupying the ATP-binding pocket inside each kinase domain, preventing the phosphorylation events that would otherwise propagate downstream growth signals. Targeting several RTKs at once, rather than one in isolation, is intended to limit compensatory escape routes: a tumor that reduces its dependence on VEGFR signaling alone might still be restrained if PDGFR- or KIT-driven pathways are also suppressed. This mechanism is broadly relevant across cancers where angiogenesis and stromal signaling contribute to tumor growth and spread.